New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial

New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial
Since the first reports of HIV infection in the early 1980s, multiple clinical trials have tested potential vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person’s immune system from mounting an effective response following HIV vaccination. An alternative anti-HIV strategy called Vectored ImmunoProphylaxis (VIP) designed by researchers at the